Journal
LUNG CANCER
Volume 41, Issue -, Pages S9-S14Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/S0169-5002(03)00134-X
Keywords
EGFR; Her-2; tyrphostins; lung cancer
Categories
Ask authors/readers for more resources
EGFR and Her-2 are overexpressed in lung cancers and have, therefore, been chosen as preferred targets for novel therapies. Recent results on Iressa trials show only a moderate response to the agent, even in cases where it is documented that EGFR is over-expressed. These findings prompted us to re-visit the oncogenic pathways, which play a rote in lung cancers, with special emphasis on the way EGFR/ Her-2 signaling cooperates with other signaling pathways. (C) 2003 Elsevier Science Ireland Ltd and Ainerican Society of Clinical Oncology. Published by Elsevier Science Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available